AC Immune (ACIU) Net Cash Flow (2015 - 2025)

AC Immune (ACIU) has 11 years of Net Cash Flow data on file, last reported at -$1.2 million in Q4 2025.

• Quarterly Net Cash Flow fell 156.67% year-over-year to -$1.2 million in Q4 2025, while the trailing twelve-month figure through Mar 2026 was $10.4 million (up 124.85% YoY) and the FY2025 annual result came in at -$10.2 million, up 78.0% from the prior year.
• Net Cash Flow declined to -$1.2 million in Q4 2025 per ACIU's latest filing, from $2.6 million in the prior quarter.
• Across five years, Net Cash Flow topped out at $54.0 million in Q4 2023 and bottomed at -$51.2 million in Q2 2021.
• The 5-year median for Net Cash Flow is -$11.4 million (2021), against an average of -$7.2 million.
• The widest annual swing landed in 2021, when Net Cash Flow plunged 1408.62%; it then soared 527.1% in 2023.
• Tracing ACIU's Net Cash Flow over 5 years: stood at -$11.2 million in 2021, then retreated by 12.8% to -$12.7 million in 2022, then jumped by 527.1% to $54.0 million in 2023, then plunged by 95.96% to $2.2 million in 2024, then tumbled by 156.67% to -$1.2 million in 2025.
• Per Business Quant, the three latest ACIU Net Cash Flow figures stand at -$1.2 million (Q4 2025), $2.6 million (Q3 2025), and $9.0 million (Q2 2025).

Peer Comparison